This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CARMIEL, Israel, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that data from select pipeline candidates and information on the Company's plant cell based technology, ProCellEx®, will be presented at upcoming scientific and medical meetings. Details regarding the conferences are as follows:
th Annual Meeting of American Association for the Study of Liver Diseases, November 1-5, 2013, Walter E. Washington Convention Center, Washington, DC.
Poster entitled, "Oral administration of a plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune mediated hepatitis," to be presented, November 3, 2013 from 8:00 AM – 5:30 PM ET
A copy of the poster will be posted on the Company's website.
Brazil's Ministry of Health- Fiocruz Plant Based Technology Meeting, November 21-22, 2013 in Fortaleza, Ceará, Brazil. The objectives of this meeting, which will be chaired by Brazil's Minister of Health and Fiocruz's president, are to discuss trends about plant based technologies, partnerships, raise awareness among the various stakeholders about plant-based technologies and disseminate information about Bio-Manguinhos/Fiocruz's new facilities at Ceará for plant-based technologies.
Protalix oral presentation on Plant Cell Culture to be given November 21, 2013 at 4:00 PM BRT
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by Israel's Ministry of Health in September 2012, by the Brazilian National Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013, and by the regulatory authorities of other countries. Marketing applications for taliglucerase alfa have been filed in additional territories as well. Protalix has partnered with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, excluding Israel and Brazil, where Protalix retains full rights. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for the treatment of certain immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; PRX-110 for the treatment of Cystic Fibrosis; PRX-107 for the treatment of emphysema due to hereditary alpha1-antitrypsin deficiency; and others.